Latest filing published 04 Aug 2022 for Cullinan Oncology, Inc., €67k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Vision SCS F2: trading record in brief
Vision SCS F2 is a declared insider of Cullinan Therapeutics, Inc., with filings sourced from SEC (Form 4). We count 8 filings; the first trade dates from 11 January 2022 and the latest from 4 August 2022.
Sales make up the whole of the open-market record (7 sales, €4.6M).
Most recently, on 4 August 2022, the filings show an open-market sale worth €268k in Cullinan Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Vision SCS F2
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,792 shares@ US$14.09732.7% of flowCommon StockSEC:0001104659-22-086343:0
- 264,072 shares@ US$9.249797.3% of flowCommon StockSEC:0001104659-22-061591:0
- 1,187,734 sharesCommon StockSEC:0000899243-22-001926:0
3 of 3 declarations
